CD24 and tumor budding as a prognostic variable in carcinoma gall bladder: A pilot study

• DOI: 10.4103/jcrt.jcrt_1986_23
• Publication Date: 2025-04-04T00:06:53Z
• Authors: Devanshi Brajesh ...; Preeti Agarwal; Ajay Kumar Singh; Malti Kumar Maurya; Shalini Bhalla; Vishal Gupta; Akshay Anand; Sameer Gupta; Abhinav Arun Sonkar
• Keywords: Tumor budding; CD24; Budding

ABSTRACT Background: CD24 is a small heavily glycosylated glycosylphosphotidylinositol-linked cell surface protein that expressed in variety of hematological and solid tumors. It majorly involved tumor development, proliferation, invasion, metastasis, prevention death via various major minor signalling pathways although it can also inhibit invasiveness degrading BART mRNA. Aim Objective: We aimed to evaluate expression gall bladder carcinoma (GBC), immunohistochemical (IHC) staining on paraffin-embedded histological tissue along with assessment budding. Material Methods: 87 patients were enrolled IHC was evaluated using four degrees positivity (negative, mild, moderate, strong). The then correlated clinicopathological parameters. Interpretation budding done the H E slide. Hotspots chosen total number buds reported an area measuring 0.785 mm 2 corresponding 20× fields microscope. Results: positive found 77.5% cases. Its inversely stage, necrosis, lymph vascular invasion establishing its usefulness as prognostic marker. Tumor poor differentiation higher grade poorly differentiated cancer responded well chemotherapy. Conclusion: Our study supports importance markers thus risk stratification GBC. CD 24 subgroup GBC cases may benefit from anti-CD24 mAb therapy we recommend be included morphological synoptic reporting cancer.